Synapse - Thoracic Oncology

Results (3406)

Larotrectinib compared with real-world non-tropomyosin receptor kinase inhibitor therapies in patients with tropomyosin receptor kinase fusion cancer

Journal Article

Brose, M. S.; Westphalen, C. B.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A.; Subbiah, V.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: A plain language summary

Editorial

Bauman, J. R.; Liu, G.; Preeshagul, I.; Melosky, B.; Abrahami, D.; Li, B.; Thomaidou, D.; Krulewicz, S.; Rupp, M.
Future Oncology (2025)

Fulltext@MSK | Save

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

Journal Article

Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Safety and tolerability of lete-cel in NSCLC—Reply

Correspondence

Altan, M.; Lopes, G.; Hiltermann, T. J. N.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer

Journal Article

Catozzi, A.; Peiris Pagès, M.; Humphrey, S.; Revill, M.; Morgan, D.; Roebuck, J.; Chen, Y.; Davies-Williams, B.; Brennan, K.; Mukarram Hossain, A. S. M.; more...
Cell Reports (2025)

Fulltext@MSK | Save

Dopamine D(2) receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Journal Article

Alam, S. K.; Pandit, A.; Wang, L.; Mortazavi Farsani, S. S.; Thiele, B. A.; Manoj, P.; Aubry, M. C.; Verma, V.; Rudin, C. M.; Lo, Y. C.; more...
Cell Death & Disease (2025)

Fulltext@MSK | Save

The lung cancer autochthonous model gene expression database enables cross-study comparisons of the transcriptomic landscapes across mouse models

Journal Article

Cai, L.; Wu, F.; Zhou, Q.; Gao, Y.; Yao, B.; DeBerardinis, R. J.; Acquaah-Mensah, G. K.; Aidinis, V.; Beane, J. E.; Biswal, S.; more...
Cancer Research (2025)

Fulltext@MSK | Save

Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors

Journal Article

Liu, D.; Jee, J.; Drilon, A.; Heilmann, A. M.; Allen, J. M.; Schrock, A. B.; Keller-Evans, R. B.; Li, B. T.
Cancer Research Communications (2025)

Fulltext@MSK | Save

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

Meeting Abstract

Le, X.; Hendriks, L.; Morabito, A.; Bonanno, L.; Okamoto, I.; Goldman, J. W.; Yu, H. A.; Brustugun, O. T.; Halvorsen, T. O.; Kim, Y. J.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes

Meeting Abstract

Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save